Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Proof-of-Performance Study of RABIOPRED Assay as an In Vitro Diagnostic Test to Identify Patients With Rheumatoid Arthritis Who Are Unlikely to Show Response to 1st Treatment With Anti-TNFα and Methotrexate Combination.

NCT03016260 is registered in ClinicalTrials.gov with TcLand Expression S.A. as lead sponsor.

NCT NCT03016260
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03016260 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Proof-of-Performance Study of RABIOPRED Assay as an In Vitro Diagnostic Test to Identify Patients With Rheumatoid Arthritis Who Are Unlikely to Show Response to 1st Treatment With Anti-TNFα and Methotrexate Combination.
Lead sponsor
TcLand Expression S.A.
Phase
Observational
Overall status
Terminated
Start date
December 31, 2016
Completion date
December 20, 2019
Enrollment
250 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis